317 related articles for article (PubMed ID: 22844557)
1. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome.
Martínez C; González-Castro A; Vicario M; Santos J
Gut Liver; 2012 Jul; 6(3):305-15. PubMed ID: 22844557
[TBL] [Abstract][Full Text] [Related]
2. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?
Piche T
Neurogastroenterol Motil; 2014 Mar; 26(3):296-302. PubMed ID: 24548256
[TBL] [Abstract][Full Text] [Related]
3. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M
Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702
[TBL] [Abstract][Full Text] [Related]
4. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome.
González-Castro AM; Martínez C; Salvo-Romero E; Fortea M; Pardo-Camacho C; Pérez-Berezo T; Alonso-Cotoner C; Santos J; Vicario M
J Gastroenterol Hepatol; 2017 Jan; 32(1):53-63. PubMed ID: 27087165
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations.
Pardo-Camacho C; Ganda Mall JP; Martínez C; Pigrau M; Expósito E; Albert-Bayo M; Melón-Ardanaz E; Nieto A; Rodiño-Janeiro B; Fortea M; Guagnozzi D; Rodriguez-Urrutia A; Torres I; Santos-Briones I; Azpiroz F; Lobo B; Alonso-Cotoner C; Santos J; González-Castro AM; Vicario M
Cells; 2022 Jun; 11(13):. PubMed ID: 35805133
[TBL] [Abstract][Full Text] [Related]
6. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
[TBL] [Abstract][Full Text] [Related]
7. Costunolide ameliorates intestinal dysfunction and depressive behaviour in mice with stress-induced irritable bowel syndrome
Li X; Liu Q; Yu J; Zhang R; Sun T; Jiang W; Hu N; Yang P; Luo L; Ren J; Wang Q; Wang Y; Yang Q
Food Funct; 2021 May; 12(9):4142-4151. PubMed ID: 33977961
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.
Ohman L; Simrén M
Nat Rev Gastroenterol Hepatol; 2010 Mar; 7(3):163-73. PubMed ID: 20101257
[TBL] [Abstract][Full Text] [Related]
9. Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.
O'Malley D
Exp Physiol; 2019 Jan; 104(1):3-10. PubMed ID: 30444291
[TBL] [Abstract][Full Text] [Related]
10. The Role of Mast Cells in Irritable Bowel Syndrome.
Lee KN; Lee OY
Gastroenterol Res Pract; 2016; 2016():2031480. PubMed ID: 28115927
[TBL] [Abstract][Full Text] [Related]
11. The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome.
Pigrau M; Rodiño-Janeiro BK; Casado-Bedmar M; Lobo B; Vicario M; Santos J; Alonso-Cotoner C
Neurogastroenterol Motil; 2016 Apr; 28(4):463-86. PubMed ID: 26556786
[TBL] [Abstract][Full Text] [Related]
12. Abnormal Barrier Function in Gastrointestinal Disorders.
Farré R; Vicario M
Handb Exp Pharmacol; 2017; 239():193-217. PubMed ID: 27995392
[TBL] [Abstract][Full Text] [Related]
13. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress.
Vicario M; Guilarte M; Alonso C; Yang P; Martínez C; Ramos L; Lobo B; González A; Guilà M; Pigrau M; Saperas E; Azpiroz F; Santos J
Brain Behav Immun; 2010 Oct; 24(7):1166-75. PubMed ID: 20600818
[TBL] [Abstract][Full Text] [Related]
14. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
Barbara G
Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
[TBL] [Abstract][Full Text] [Related]
15. The immune system in irritable bowel syndrome.
Barbara G; Cremon C; Carini G; Bellacosa L; Zecchi L; De Giorgio R; Corinaldesi R; Stanghellini V
J Neurogastroenterol Motil; 2011 Oct; 17(4):349-59. PubMed ID: 22148103
[TBL] [Abstract][Full Text] [Related]
16. Intestinal barrier function in health and gastrointestinal disease.
Camilleri M; Madsen K; Spiller R; Greenwood-Van Meerveld B; Verne GN
Neurogastroenterol Motil; 2012 Jun; 24(6):503-12. PubMed ID: 22583600
[TBL] [Abstract][Full Text] [Related]
17. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside.
Zhang L; Song J; Hou X
J Neurogastroenterol Motil; 2016 Apr; 22(2):181-92. PubMed ID: 26755686
[TBL] [Abstract][Full Text] [Related]
18. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review.
Hanning N; Edwinson AL; Ceuleers H; Peters SA; De Man JG; Hassett LC; De Winter BY; Grover M
Therap Adv Gastroenterol; 2021; 14():1756284821993586. PubMed ID: 33717210
[TBL] [Abstract][Full Text] [Related]
19. Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome.
Zhao DY; Qi QQ; Long X; Li X; Chen FX; Yu YB; Zuo XL
Physiol Int; 2019 Sep; 106(3):225-235. PubMed ID: 31560236
[TBL] [Abstract][Full Text] [Related]
20. The role of intestinal mast cell infiltration in irritable bowel syndrome.
Cheng L; Luo QQ; Chen SL
J Dig Dis; 2021 Mar; 22(3):143-151. PubMed ID: 33511763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
